HRAS - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
MUTYH	mutY DNA glycosylase			Familial adenomatous polyposis
NF1	neurofibromin 1	Regulation of RAS by GAPs RAS signaling downstream of NF1 loss-of-function variants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
NRAS	NRAS proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
PDE4D	phosphodiesterase 4D	DARPP-32 events G alpha (s) signalling events	Adenosine phosphate Caffeine Caffeine Dyphylline Iloprost Amrinone Roflumilast Piclamilast Rolipram 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol Zardaverine 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester (S)-Rolipram Cilomilast (R)-Rolipram 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester Crisaborole Ibudilast Tetomilast Exisulind (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER 3-isobutyl-1-methyl-7H-xanthine 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid Trapidil
PDE6D	phosphodiesterase 6D	ARL13B-mediated ciliary trafficking of INPP5E RAS processing
PDGFB	platelet derived growth factor subunit B	Platelet degranulation PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer Non-integrin membrane-ECM interactions RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pegpleranib	Malignant pleural mesothelioma Glioma
PDGFRL	platelet derived growth factor receptor like
PI4K2A	phosphatidylinositol 4-kinase type 2 alpha	Synthesis of PIPs at the plasma membrane Synthesis of PIPs at the Golgi membrane Synthesis of PIPs at the early endosome membrane
PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Extra-nuclear estrogen signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	ATP Caffeine XL765 Wortmannin Pilaralisib Alpelisib Copanlisib	Ovarian cancer
PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	PIP3 activates AKT signaling Synthesis of PIPs at the plasma membrane Constitutive Signaling by Aberrant PI3K in Cancer Interleukin-3, Interleukin-5 and GM-CSF signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Caffeine XL765 TG100-115 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE Idelalisib Duvelisib Fostamatinib Copanlisib
PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	GPVI-mediated activation cascade Synthesis of PIPs at the plasma membrane G beta:gamma signalling through PI3Kgamma Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	Staurosporine Myricetin LY-294002 Quercetin 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE XL765 TG100-115 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE Wortmannin 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Duvelisib Fostamatinib
PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Costimulation by the CD28 family CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Extra-nuclear estrogen signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Isoprenaline SF1126 Enzastaurin Wortmannin
PLA2G4B	phospholipase A2 group IVB	Acyl chain remodelling of PC Acyl chain remodelling of PS Acyl chain remodelling of PE Acyl chain remodelling of PG Hydrolysis of LPC Synthesis of PA XBP1(S) activates chaperone genes
PLAAT4	phospholipase A and acyltransferase 4	Acyl chain remodelling of PE
PLCE1	phospholipase C epsilon 1	Synthesis of IP3 and IP4 in the cytosol		Nephrotic syndrome and focal segmental glomerulosclerosis
PLCH2	phospholipase C eta 2	Synthesis of IP3 and IP4 in the cytosol
PRKCI	protein kinase C iota	Pre-NOTCH Transcription and Translation p75NTR recruits signalling complexes Tight junction interactions	Tamoxifen Bisindolylmaleimide I Fostamatinib
PRKCZ	protein kinase C zeta	GPVI-mediated activation cascade TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) VEGFR2 mediated cell proliferation RHO GTPases Activate NADPH Oxidases Estrogen-stimulated signaling through PRKCZ Estrogen-stimulated signaling through PRKCZ	Tamoxifen
PRSS50	serine protease 50
PTPRJ	protein tyrosine phosphatase receptor type J	Phosphorylation of CD3 and TCR zeta chains Neutrophil degranulation Negative regulation of MET activity Negative regulation of FLT3

Search Results for: HRAS